Stemtech Valuation
Is STEK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of STEK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate STEK's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate STEK's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for STEK?
Key metric: As STEK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is STEK's PS Ratio? | |
|---|---|
| PS Ratio | 0.5x |
| Sales | US$5.37m |
| Market Cap | US$2.89m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | -1.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does STEK's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.8x | ||
HYEX Healthy Extracts | 2.1x | n/a | US$3.6m |
CYAN Cyanotech | 0.1x | n/a | US$2.7m |
ELAB Elevai Labs | 0.4x | n/a | US$1.1m |
SISI Shineco | 0.3x | n/a | US$3.3m |
STEK Stemtech | 0.5x | n/a | US$2.9m |
Price-To-Sales vs Peers: STEK is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.8x).
Price to Sales Ratio vs Industry
How does STEK's PS Ratio compare vs other companies in the US Personal Products Industry?
Price-To-Sales vs Industry: STEK is good value based on its Price-To-Sales Ratio (0.5x) compared to the US Personal Products industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is STEK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate STEK's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Ascend Wellness Holdings
US$100.8m
Engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States.
AAWH
US$0.47
7D
-17.0%
1Y
-59.9%
Kimberly-Clark de México S. A. B. de C. V
Mex$86.8b
Manufactures, distributes, and sells disposable products in Mexico.
KCDM.F
Mex$1.45
7D
0%
1Y
n/a
Beauty Health
US$200.5m
Designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide.
SKIN
US$1.62
7D
-12.7%
1Y
-27.4%